Xzōm – Early Enough. Xzōm is pioneering the future of early disease detection through its proprietary liquid biopsy platform, which leverages on-chip exosome analysis to deliver clinical-grade diagnostic sample to answer results in 30 minutes or less. Designed for rapid, point-of-care testing, Xzōm’s technology empowers timely and accurate detection across a broad range of applications including oncology, neurological conditions, infectious diseases, and beyond. With a mission to make lifesaving diagnostics accessible and affordable for all, Xzōm is shifting the healthcare paradigm—from reactive, late-stage intervention to proactive, early-stage detection. By enabling providers and patients to act earlier, Xzōm is helping unlock better outcomes and a more efficient, equitable healthcare system.